Act Now, Supplies Are Limited
May 5, 2009 5:26 PM Subscribe
Raptiva, an immunosuppressant used to treat severe plaque psoriasis, caught the attention of the FDA as triggering the activation of the John Cunningham virus. Present in 70% to 90% of human beings, the virus, once activated, inflames the white matter of the brain - a condition known as progressive multifocal leukoencephalitis (PML) - which has no cure and is almost always fatal. Although the FDA recognized the link between Raptiva and PML last autumn, it wasn't until last month that Genentech, the manufacturers of the drug, issued a voluntary withdrawal, and even then, are still allowing people who use Raptiva to continue to get refills until June 8.
This thread has been archived and is closed to new comments